MRKR Profile
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is at the forefront of developing and commercializing innovative T cell-based immunotherapies and peptide-based vaccines aimed at treating both hematological malignancies and solid tumors. Founded in 1999 and headquartered in Houston, Texas, Marker Therapeutics leverages its proprietary MultiTAA-specific T cell technology to create therapies that target multiple tumor-associated antigens. This approach involves the use of non-engineered tumor-specific T cells designed to recognize and eliminate cancer cells expressing these antigens.
The company's MultiTAA-specific T cell therapies encompass a range of products including autologous T cells, which are tailored for treating lymphoma and various solid tumors, as well as allogeneic T cells intended for addressing acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Additionally, Marker Therapeutics is developing off-the-shelf T cell products for multiple indications, aiming to provide accessible and scalable treatment options. This innovative approach is designed to enhance the effectiveness of immunotherapy by targeting a broader spectrum of tumor antigens.
Marker Therapeutics is also advancing its peptide-based immunotherapeutic vaccines, with TPIV100/110 being developed for the treatment of breast and ovarian cancer. TPIV200, another key product, is currently undergoing Phase 2 clinical trials to evaluate its efficacy in treating these cancers. These vaccines aim to stimulate the immune system to target and destroy cancer cells, offering a promising therapeutic avenue for patients with challenging cancer types.
By focusing on cutting-edge immunotherapy technologies and peptide-based vaccines, Marker Therapeutics is positioning itself as a leader in the field of cancer treatment. The company's commitment to advancing novel therapies underscores its dedication to improving patient outcomes and expanding the arsenal of tools available for combating cancer. Through ongoing research and clinical development, Marker Therapeutics continues to work towards bringing innovative and effective treatments to market.
|
